

Jonathan L Curry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7482682/publications.pdf>

Version: 2024-02-01

77
papers

4,829
citations

279798

23
h-index

106344

65
g-index

78
all docs

78
docs citations

78
times ranked

8278
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous Lymphoid Hyperplasia With T-Cell Clonality and Monotypic Plasma Cells Secondary to a Tick Bite: A Hidden Critter and the Power of Deeper Levels. <i>American Journal of Dermatopathology</i> , 2022, 44, 226-229.	0.6	2
2	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	1.3	5
3	Ibrutinib skin toxicities: Report of two cases. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 363-368.	1.3	2
4	Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance. <i>Haematologica</i> , 2022, 107, 1880-1890.	3.5	6
5	Eosinophilic homogeneous intracytoplasmic inclusion bodies: Unique viral cytopathic changes associated with epidermodysplasia verruciformis and human papillomavirus type 49. <i>Journal of Cutaneous Pathology</i> , 2022, , .	1.3	1
6	Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 472-481.	1.3	7
7	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
8	Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 859-867.	1.3	10
9	Cutaneous adnexal carcinosarcoma: Immunohistochemical and molecular evidence of epithelial mesenchymal transition. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 526-534.	1.3	1
10	Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 547-557.	1.3	3
11	Plasma cell myeloma with immature plasma cells in the skin arising within the areas of chronic stasis dermatitis. <i>JAAD Case Reports</i> , 2021, 7, 26-29.	0.8	0
12	Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 674-679.	1.3	4
13	Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. <i>Frontiers in Oncology</i> , 2021, 11, 621591.	2.8	29
14	Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma. <i>JAAD Case Reports</i> , 2021, 10, 82-84.	0.8	8
15	Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade. <i>Surgical Pathology Clinics</i> , 2021, 14, 209-224.	1.7	3
16	PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1680-1691.	4.1	22
17	Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1. <i>JAAD Case Reports</i> , 2021, 13, 23-25.	0.8	2
18	Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 842-850.	2.5	0

#	ARTICLE	IF	CITATIONS
19	Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. <i>JAAD Case Reports</i> , 2021, 17, 34-37.	0.8	1
20	Localized cutaneous argyria: Review of a rare clinical mimicker of melanocytic lesions. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151776.	1.3	4
21	The utility of digital pathology in improving the diagnostic skills of pathology trainees in commonly encountered pigmented cutaneous lesions during the COVID-19 pandemic: A single academic institution experience. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151807.	1.3	7
22	Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 943-952.	2.5	8
23	Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 36-46.	1.3	2
24	Pembrolizumab-Induced Stevensâ€“Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report. <i>American Journal of Dermatopathology</i> , 2020, 42, 292-296.	0.6	21
25	Hypertrophic lichenoid dermatitis immuneâ€“related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 954-959.	1.3	8
26	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	27.8	1,421
27	Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 490-493.	1.3	4
28	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2146-2156.e4.	0.7	14
29	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immuneâ€“related adverse event with mycosisâ€“fungoidesâ€“like morphologic and molecular features. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 872-877.	1.3	4
30	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. <i>Cancers</i> , 2019, 11, 754.	3.7	21
31	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 860-865.	3.4	76
32	Gene expression profiling of lichenoid dermatitis immuneâ€“related adverse event from immune checkpoint inhibitors reveals increased CD14 ⁺ and CD16 ⁺ monocytes driving an innate immune response. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 627-636.	1.3	27
33	Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. <i>Cancers</i> , 2019, 11, 1714.	3.7	5
34	Postâ€“radiation vascular lesions of the breast. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 52-58.	1.3	17
35	Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. <i>Journal of Clinical Pathology</i> , 2019, 72, 265-270.	2.0	21
36	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 545-549.	1.3	5
38	Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 539-544.	1.3	13
39	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 504-507.	1.3	25
40	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
41	Extensive ulcerated lesions in a patient with cutaneous myeloid sarcoma responded to twice-daily fludarabine and cytarabine regimen. <i>Blood Cells, Molecules, and Diseases</i> , 2018, 69, 43-44.	1.4	1
42	Juvenile mycosis fungoides with large cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon- α , and localized radiation. <i>Pediatric Dermatology</i> , 2018, 35, e13-e16.	0.9	3
43	Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. <i>Journal of Cutaneous Pathology</i> , 2018, 46, 152-158.	1.3	5
44	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
45	Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 764-773.	1.3	38
46	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 786-790.	1.3	18
47	Concomitant Cutaneous Langerhans Cell Histiocytosis and Leukemia Cutis. <i>American Journal of Dermatopathology</i> , 2017, 39, 388-392.	0.6	11
48	Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. <i>American Journal of Dermatopathology</i> , 2017, 39, 121-129.	0.6	96
49	Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall. <i>American Journal of Dermatopathology</i> , 2017, 39, 468-470.	0.6	3
50	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1080-1086.	1.3	48
51	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1075-1079.	1.3	27
52	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176.	1.3	186
53	A case of indeterminate dendritic cell tumor presenting with leonine facies. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 158-163.	1.3	12
54	Autoimmune dermatologic toxicities from immune checkpoint blockade with anti- PD-1 antibody therapy: a report on bullous skin eruptions. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 688-696.	1.3	126

#	ARTICLE	IF	CITATIONS
55	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5553-5563.	7.0	96
56	A case report of Grover's disease from immunotherapy—a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50
57	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785
58	¹⁸ F-NP63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. <i>Cancer Cell</i> , 2016, 29, 874-888.	16.8	32
59	Cutaneous metastasis from anaplastic thyroid carcinoma exhibiting exclusively a spindle cell morphology. A case report and review of literature. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 252-257.	1.3	8
60	BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. <i>Human Pathology</i> , 2016, 50, 79-89.	2.0	18
61	Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma. <i>American Journal of Dermatopathology</i> , 2015, 37, e96-e99.	0.6	18
62	Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. <i>BMC Dermatology</i> , 2015, 15, 2.	2.1	15
63	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015, 46, 1101-1110.	2.0	43
64	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	138
65	Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 326-328.	1.3	28
66	Histological Features Associated With Vemurafenib-Induced Skin Toxicities. <i>American Journal of Dermatopathology</i> , 2014, 36, 557-561.	0.6	17
67	Detection of mitotic figures and <sc>G2</sc>+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 846-852.	1.3	16
68	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. <i>International Journal of Dermatology</i> , 2014, 53, 376-384.	1.0	62
69	Tissue Resources for Clinical Use and Marker Studies in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 679-695.	0.9	7
70	Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor. <i>American Journal of Dermatopathology</i> , 2013, 35, 125-128.	0.6	5
71	Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 267-273.	1.6	48
72	Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. <i>Expert Review of Dermatology</i> , 2011, 6, 355-357.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/SÅ©zary syndrome. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 295-297.	1.3	13
74	Reactivity of Resident Immunocytes in Normal and Prepsoriatic Skin Using an Ex Vivo Skin-Explant Model System. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 289-296.	2.5	28
75	Innate Immune-Related Receptors in Normal and Psoriatic Skin. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 178-186.	2.5	123
76	CORTICOTROPIN RELEASING HORMONE AND RELATED PEPTIDES CAN ACT AS BIOREGULATORY FACTORS IN HUMAN KERATINOCYTES. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2000, 36, 211.	1.5	58
77	Amyloid deposition with a granulomatous reaction in a resection specimen: A clue for a preexisting Merkel cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 0, , .	1.3	0